^
    Back
    Association details:
    Biomarker:FGFR1 amplification
    Cancer:Breast Cancer
    Drug Class:Aromatase inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Clin Transl Oncol
    Title:

    CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer

    Published date:
    09/02/2020
    Excerpt:
    Presence of CCND1 and/or FGFR1 amplification is associated with worse outcomes of AI therapy in patients with metastatic BC.
    DOI:
    10.1007/s12094-020-02481-w